Chemotherapy-Induced Myelosuppression Treatment Market to Register a Stellar Growth Rate of CAGR of 3.2% During 2018-2028

1
Chemotherapy-Induced Myelosuppression Treatment
Market

• January 2019

Report Id REP-GB-1364 Published On
Jan-2019 Category Healthcare, Pharmaceuticals
Medical Devices
2
AboutFuture Market Insights
Future Market Insights (FMI) is a premier
provider of syndicated research reports, custom
research reports, and consulting services. We
deliver a complete packaged solution, which
combines current market intelligence, statistical
anecdotes, technology inputs, valuable growth
insights, aerial view of the competitive
framework, and future market trends. We provide
research services at a global as well as regional
level key regions include GCC, ASEAN,
and BRIC. Our offerings cover a broad spectrum of
industries including Chemicals, Materials,
Energy, Technology, Healthcare, and Retail. We
have a global presence with delivery centers
across India specializing in providing global
research reports and country research reports.
FMI is headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune,
India. We combine our knowledge and learning from
every corner of the world to distill it to one
thing the perfect solution for our client.
Research Capabilities
Sector Coverage

• Customized Research
• Syndicated Research
• Investment Research
• Social Media Research

• Automotive and Transportation
• Electronics, Semiconductor, and ICT
• Retail and Consumer Products
• Industrial Automation and Equipment

• Chemicals Materials
• Food and Beverages
• Services and Utilities
• Energy, Mining, Oil, and Gas

Subscription Information

For detailed subscription information please
contact Hari. T (Sr. Manager - Global Business
Development) T 44 (0) 20 7692 8790 D 44
20 3287 4268 Email hari.t_at_futuremarketinsights.co
m
3
Research Methodology (1/2)

• Systematic Research Approach

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc.
FMI formulates a detailed discussion guide to conduct expert and industry interviews
FMI develops a list of industry players (manufacturers), distributors, retailers and industry experts
FMI conducts interviews with industry experts, industry players, distributors and retailers
Data is validated by triangulation method, wherein secondary, primary and FMI analysis contribute to the final data
Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry
FMI delivers industry insights and information in the required format (PDF)

• Identifying key opinion leaders
• Questionnaire design
• In-depth interviews
• Coverage across value chain

• Key industry experts
• Channel study
• Developments
• Market dynamics
• Products
• Conclusions

SOLUTION

• Market participants
• Key strengths
• Product portfolio
• Mapping as per value chain
• Key focus segments

Primary Research
Secondary Research
Paid Publications

• Linkedin
• Zoominfo
• Salesforce
• Avention

• Factiva
• GBI
• Genios
• Meltwater

• Company websites
• Company annual reports
• White papers
• Financial reports

includes sources of databases
4
Chemotherapy-Induced Myelosuppression Treatment
MarketAnalysis

• Research delivers insight into the
  Chemotherapy-Induced Myelosuppression Treatment
  Market  poised to expand at 3.2 CAGR by
  2018-2028
• VALLEY COTTAGE -- A new study by FMI reveals that
  the chemotherapy-induced myelosuppression
  treatment market is expected to grow at a subdued
  3 y-o-y in 2019. Valued at nearly US 7 billion
  in 2018, gains are likely to be driven by a
  combination of multipronged factors, including,
• Development of natural product interventions for
  chemotherapy-induced side effects
• Growing implementation of radiation treatment in
  cancer treatment owing to the associated high
  success rate of chemotherapy
• Growing RD investments in cancer research
• The FMI study finds that growth factor drugs
  continued to garner highest revenues in
  the chemotherapy-induced myelosuppression
  treatment market. In 2018, over 73 of the
  chemotherapy-induced myelosuppression treatment
  market revenues were consolidated in the growth
  factors. Gains were especially notable for
  granulocyte-colony stimulating factor or G-CSF,
  which accounted for over 60 of the global
  chemotherapy-induced myelosuppression treatment
  market revenues in 2018.

5
Chemotherapy-Induced Myelosuppression Treatment
MarketAnalysis

• The FMI study reveals that erythropoietin-stimulat
  ing agents (ESA) also accounted for a significant
  market share, with revenues likely to grow at
  2.8 in 2019. In April 2017, FDA announced the
  removal of risk evaluation and mitigation
  strategy (REMS) requirement for the use of ESA
  drugs in myelosuppression treatment. The ESAs
  used in the treatment of radiation-induced
  myelosuppression treatment are epoetin alfa and
  darbepoetin alfa. This has led healthcare
  professionals to engage in the practice of
  discussing benefits as well as risks of
  treatments that include ESAs before initiating
  the use.
• Hematopoietic growth factors have transformed the
  practice of cancer treatment by allowing
  stimulation of production of specific cells. With
  this, use of thrombopoietin receptor agonists is
  expected to rise rapidly at the rate of 3.5 in
  2019.
• Injectable Drugs Present Higher Therapeutic
  Availability over Orals
• The FMI study finds that injectable drugs
  accounted for over 97 of the chemotherapy-induced
  myelosuppression treatment market revenues in
  2018. The status-quo will continue in the future,
  however, the oral route of administration is
  expected to garner increasing annual revenues and
  expected to grow at 4.8 in 2019 over 2018.
• Increasing number of research validations related
  to the benefits of the oral route of
  administration can be attributed to the higher
  growth rate of the segment in the future.
  However, revenues from the injectable route of
  the administration continue to grow steadily on
  the back of their higher therapeutic availability
  over orally administered drugs.

6
Chemotherapy-Induced Myelosuppression Treatment
MarketAnalysis

• Market Revenues Consolidated in Neutropenia
  Treatment
• According to the study, chemotherapy-induced
  myelosuppression treatment market revenues
  heavily consolidated in the neutropenia
  treatment. In 2018, neutropenia indication
  accounted for over 62 of market revenues. As
  neutropenia is one of the most common side
  effects of chemotherapy wherein prolongation of
  the same can lead to life-threatening infections.
  Owing to the severity of the implications,
  chemotherapy-induced myelosuppression
  therapeutics are heavily used in the treatment of
  neutropenia.
• Anemia and thrombocytopenia indications also
  utilize chemotherapy-induced myelosuppression
  treatment therapeutics. The study finds that
  revenues in the thrombocytopenia treatment will
  grow at 3.7 y-o-y in 2019.
• Retail Pharmacies Most Prominent Sales Channel
• The study opines that chemotherapy-induced
  myelosuppression treatment therapeutics sales
  remain higher through retail pharmacies.
  Suppliers of these therapeutics have extensive
  distribution network with international retail
  pharmacies. Due to this, retail pharmacies
  accounted for over 48 of the chemotherapy-induced
  myelosuppression treatment market revenues in
  2018.

7
Chemotherapy-Induced Myelosuppression Treatment
MarketAnalysis

• Owing to heavy integration of pharmacies in the
  hospitals, distribution of chemotherapy-induced
  myelosuppression treatment therapeutics through
  hospital pharmacies also account for a
  considerable share of the market revenues. The
  study finds that hospital pharmacies can be
  called the second largest distributor of
  chemotherapy-induced myelosuppression treatment
  therapeutics owing to their 45 of the market
  revenues.
• US The Worlds Largest Chemotherapy-induced
  Myelosupression Treatment Market
• FMI reveals that North America accounted for over
  82 of the revenues in chemotherapy-induced
  myelosuppression treatment market in 2018.
  Presence of leading cancer therapeutics
  providers, significant RD investments and
  established healthcare sector contribute to the
  bulk of market revenues. The U.S. remains the
  largest consumer of the chemotherapy-induced
  myelosuppression treatment market. 
• Market revenues in the APEJ region are likely to
  grow at higher rate owing to improving healthcare
  facility and growing penetration of advanced
  cancer care treatments. China, followed by India,
  accounts for the highest market revenues in APEJ
  owing to improving economic scenario and
  developing healthcare infrastructure.

8
Chemotherapy-Induced Myelosuppression Treatment
MarketAnalysis

• More from Healthcare, Pharmaceuticals and Medical
  Devices Market
• Retinal Biologics Market Segmentation by Drug
  Class (VEGF-An antagonist, TNF-a inhibitor) by
  Indication (Macular Degeneration, Diabetic
  Retinopathy, Diabetic Macular Edema, Uveitis,
  Others) by Distributional Channel (Institutional
  Sales, Brain Monitoring System Market Segmentation
  By Product Type (Functional Near-Infrared
  Spectroscopy (fNIRS), Electroencephalography
  (EEG) Systems, Magnetoencephalography (MEG)
  Systems, MRI Systems, Other Brain Monitoring
  Systems) By Modality (Portable/Handheld Systems,
  Standalone Systems) By End User (Hospitals,
  Ambulatory Surgical Centers, Clinics, Pediatric
  Neonatal Intensive care Units .
• 3D Cell Culture Market Segmentation By Product
  Type (Scaffold-Free 3D Cell Culture,
  Scaffold-Based 3D Cell Culture) By Applications
  (Drug Discovery, Tissue Regeneration
  Regenerative Medicines, Cancer Research, Stem
  Cell Technology, Others) By End User
  (Biotechnology and Pharmaceuticals Industries,
  Hospital Laboratories, Academic Research
  Institutes, Contract Research Organizations.
• Press-release Source - https//www.globenewswire.c
  om/news-release/2019/02/04/1709903/0/en/Chemothera
  py-Induced-Myelosuppression-Treatment-Market-is-Po
  ised-to-Exhibit-A-Moderate-3-2-CAGR-by-2028-Future
  -Market-Insights.html

9
Chemotherapy-Induced Myelosuppression Treatment
MarketAnalysis

• More Related Press-release-
• https//marketresearchcentre.business.blog/2020/02
  /25/necrotic-enteritis-treatment-market-research-t
  o-witness-a-pronounce-growth-during-2018-2028/
• https//medium.com/_at_mahi041988/necrotic-enteritis-
  treatment-market-research-will-reflect-significant
  -growth-prospects-during-7f965a44b1d3
• https//www.agreatertown.com/valley_cottage_ny/nec
  rotic_enteritis_treatment_market_research_to_hold_
  a_high_potential_for_growth_by_2018_2028_000754024
  4
• About Us
• Future Market Insights (FMI) is a leading market
  intelligence and consulting firm. We deliver
  syndicated research reports, custom research
  reports and consulting services which are
  personalized in nature. FMI delivers a complete
  packaged solution, which combines current market
  intelligence, statistical anecdotes, technology
  inputs, valuable growth insights and an aerial
  view of the competitive framework and future
  market trends.

10
Chemotherapy-Induced Myelosuppression Treatment
MarketAnalysis

• Contact UsMr. Abhishek Budholiya616 Corporate
  Way, Suite 2-9018Valley Cottage, NY 10989United
  StatesT 1-347-918-3531F 1-845-579-5705T
  (UK) 44(0)20-7692-8790Sales sales_at_futuremarket
  insights.com

11
To know more about us, please visit our website
www.futuremarketinsights.com For sales queries
or new topics email us on sales_at_futuremarketinsi
ghts.com For media queries, contact the press
office at press_at_futuremarketinsights.com For
other queries contactHari. T (Sr. Manager -
Global Business Development) Future Market
Insights 3rd Floor,207 Regent Street, London
W1B 3HH T 44 20 7692 8790 D 44 20 3287
4268 Email hari.t_at_futuremarketinsights.com
Thank You
Future Market Insights Global Consulting
Private Limited (FMI)